<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Head and Neck Tumors</journal-id><journal-title-group><journal-title xml:lang="en">Head and Neck Tumors</journal-title><trans-title-group xml:lang="ru"><trans-title>Опухоли головы и шеи</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2222-1468</issn><issn publication-format="electronic">2411-4634</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">846</article-id><article-id pub-id-type="doi">10.17650/2222-1468-2022-12-4-71-80</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL REPORT</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Retrospective comparison of individual risk factors hemithyroidectomy and thyroidectomy in patients with papillary carcinoma of the thyroid gland in combination with autoimmune thyroiditis</article-title><trans-title-group xml:lang="ru"><trans-title>Ретроспективное сопоставление индивидуальных факторов риска гемитиреоидэктомии и тиреоидэктомии у пациентов с папиллярной микрокарциномой щитовидной железы, возникшей на фоне аутоиммунного тиреоидита</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4045-5053</contrib-id><name-alternatives><name xml:lang="en"><surname>Ryabchenko</surname><given-names>E. V.</given-names></name><name xml:lang="ru"><surname>Рябченко</surname><given-names>Е. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Evgeny Viktorovich Ryabchenko</p><p>6/2 Krasnye Partizan St., Krasnodar 350012</p></bio><bio xml:lang="ru"><p>Евгений Викторович Рябченко</p><p>350012 Краснодар, ул. Красных партизан, 6/2</p></bio><email>rev7512@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Interterritorial Center for Endocrine Surgery, Regional Clinical Hospital No. 2</institution></aff><aff><institution xml:lang="ru">Межтерриториальный центр эндокринной хирургии ГБУЗ «Краевая клиническая больница № 2»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-12-10" publication-format="electronic"><day>10</day><month>12</month><year>2022</year></pub-date><volume>12</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>71</fpage><lpage>80</lpage><history><date date-type="received" iso-8601-date="2023-03-09"><day>09</day><month>03</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-03-09"><day>09</day><month>03</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Ryabchenko E.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, Рябченко Е.В.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Ryabchenko E.V.</copyright-holder><copyright-holder xml:lang="ru">Рябченко Е.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ogsh.abvpress.ru/jour/article/view/846">https://ogsh.abvpress.ru/jour/article/view/846</self-uri><abstract xml:lang="en"><p><bold>Introduction. </bold>Papillary thyroid carcinoma is the most common subtype of thyroid cancer as it comprises 95 % of cases. Frequently, this pathology develops in the presence of autoimmune thyroiditis (Hashimoto’s thyroiditis) which is the main cause of hypothyroidism in various rich in iodine regions. Papillary thyroid carcinoma is characterized by good prognosis, however some patients experience recurrence which depends on the volume of surgical intervention.</p><p><bold>Aim. </bold>To compare clinical outcomes and complications after hemithyroidectomy (HE) and thyroidectomy (TE) in patients with papillary thyroid carcinoma secondary to autoimmune thyroiditis.</p><p><bold>Materials and methods. </bold>The retrospective study included 2031 patients with papillary thyroid carcinoma. Considering individual risk factors, 67 patients were excluded from the HE group, and 588 patients were excluded from the TE group. Each group included 688 patients for whom data were matched. Such individual factors as age, sex, primary tumor size, extrathyroidal invasion, multifocal tumor and cervical lymph node metastasis were taken into account.</p><p><bold>Results. </bold>During 10‑year follow-up, recurrence was diagnosed in 26 (3.8 %) patients of the HE group and 11 (1.6 %) patients of the TE group. Relative risk of recurrence was significantly lower after TE than after HE (risk ratio (RR) 0.41; 95 % confidence interval (CI) 0.21–0.81; <italic>р</italic><italic> </italic>= 0.01). In the HE group, for the majority of patients recurrence was observed in the contralateral lobe of the thyroid (84.6 %). In the TE group, there were no recurrences in all patients. There were no significant differences between the groups after exclusion of recurrence in the contralateral thyroid lobe (RR 2.75; 95 % CI 0.08–8.79; <italic>р</italic><italic> </italic>= 0.08). In the TE group, the number of patients with transient and permanent hypothyroidism in the TE group was significantly higher than in the HE group (<italic>р</italic><italic> </italic>&lt;0.001).</p><p><bold>Conclusion. </bold>Hemithyroidectomy is appropriate for the majority of patients with papillary thyroid carcinoma in the absence of extrathyroidal invasion in the neighboring tissues per preoperative examination. For patients after HE, preoperative and postoperative diagnostic examinations are important as most recurrences develop in the contralateral thyroid lobe.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение. </bold>Папиллярная карцинома щитовидной железы является наиболее распространенным подтипом рака щитовидной железы: на ее долю приходится более 95 % случаев. Зачастую данная патология возникает на фоне аутоиммунного тиреоидита (тиреоидита Хашимото), который служит главной причиной гипотиреоза в разных регионах, богатых йодом. Папиллярная карцинома щитовидной железы характеризуется хорошим прогнозом, хотя у некоторых пациентов развивается рецидив заболевания, который зависит от объема оперативного вмешательства.</p><p><bold>Цель исследования </bold>– сравнить клинические исходы и осложнения после гемитиреоидэктомии (ГЭ) и тиреоидэктомии (ТЭ) у пациентов с папиллярной карциномой щитовидной железы, возникшей на фоне аутоиммунного тиреоидита.</p><p><bold>Материалы и методы. </bold>В ретроспективном исследовании участвовал 2031 пациент с папиллярной карциномой щитовидной железы. С учетом индивидуальных факторов риска из группы ГЭ были исключены 67 больных, а из группы ТЭ – 588 больных. В каждую группу вошли 688 пациентов, данные которых были сопоставлены. Учитывались такие индивидуальные факторы, как возраст, пол, размер первичной опухоли, экстратиреоидная инвазия, мультифокальная форма опухоли и метастазирование в шейные лимфатические узлы.</p><p><bold>Результаты. </bold>В течение 10‑летнего наблюдения у 26 (3,8 %) пациентов группы ГЭ и 11 (1,6 %) группы ТЭ отмечен рецидив. Относительный риск его развития был достоверно меньше после ТЭ, чем после ГЭ (отношение рисков (ОР) 0,41; 95 % доверительный интервал (ДИ) 0,21–0,81; <italic>р </italic>= 0,01). В группе ГЭ большинство рецидивов наблюдалось в контралатеральной доле щитовидной железы (84,6 %). В группе ТЭ у всех пациентов отсутствовал рецидив. Достоверных различий между группами после исключения рецидива в контралатеральной доле щитовидной железы не выявлено (ОР 2,75; 95 % ДИ 0,08–8,79; <italic>р </italic>= 0,08). Пациентов с транзиторным и перманентным гипопаратиреозом в группе ТЭ оказалось достоверно больше, чем в группе ГЭ (<italic>р </italic>&lt;0,001).</p><p><bold>Заключение. </bold>Проведение ГЭ целесообразно для большинства пациентов с папиллярной карциномой щитовидной железы, если по результатам предоперационного исследования отсутствует экстратиреоидная инвазия в окружающие ткани. Для больных, которым выполнена ГЭ, важны предоперационные и послеоперационные диагностические исследования, поскольку большая часть рецидивов возникает в контралатеральной доле щитовидной железы.</p></trans-abstract><kwd-group xml:lang="en"><kwd>thyroid gland</kwd><kwd>papillary cancer</kwd><kwd>autoimmune thyroiditis</kwd><kwd>hemithyroidectomy</kwd><kwd>thyroidectomy</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>щитовидная железа</kwd><kwd>папиллярный рак</kwd><kwd>аутоиммунный тиреоидит</kwd><kwd>гемитиреоидэктомия</kwd><kwd>тиреоидэктомия</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Cho B.Y., Choi H.S., Park Y.J. et al. Changes in the clinicopathological characteristics and outcomes of thyroid cancer in Korea over the past four decades. Thyroid 2013;23(7):797–804. DOI: 10.1089/thy.2012.0329</mixed-citation><mixed-citation xml:lang="ru">Cho B.Y., Choi H.S., Park Y.J. et al. Changes in the clinicopathological characteristics and outcomes of thyroid cancer in Korea over the past four decades. Thyroid 2013;23(7):797–804. DOI: 10.1089/thy.2012.0329</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Davies L., Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 2006;295(18):2164–7. DOI: 10.1001/jama.295.18.2164</mixed-citation><mixed-citation xml:lang="ru">Davies L., Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 2006;295(18):2164–7. DOI: 10.1001/jama.295.18.2164</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Elisei R., Molinaro E., Agate L. et al. Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J Clin Endocrinol Metab 2010;95(4):1516–27. DOI: 10.1210/jc.2009-1536</mixed-citation><mixed-citation xml:lang="ru">Elisei R., Molinaro E., Agate L. et al. Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J Clin Endocrinol Metab 2010;95(4):1516–27. DOI: 10.1210/jc.2009-1536</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. McNally R.J., Blakey K., James P.W. et al. Increasing incidence of thyroid cancer in great Britain, 1976–2005: age-period-cohort analysis. Eur J Epidemiol 2012;27(8):615–22. DOI: 10.1007/s10654-012-9710-x</mixed-citation><mixed-citation xml:lang="ru">McNally R.J., Blakey K., James P.W. et al. Increasing incidence of thyroid cancer in great Britain, 1976–2005: age-period-cohort analysis. Eur J Epidemiol 2012;27(8):615–22. DOI: 10.1007/s10654-012-9710-x</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Jeon M.J., Kim W.G., Choi Y.M. et al. Features predictive of distant metastasis in papillary thyroid microcarcinomas. Thyroid 2016;26(1):161–8. DOI: 10.1089/thy.2015.0375</mixed-citation><mixed-citation xml:lang="ru">Jeon M.J., Kim W.G., Choi Y.M. et al. Features predictive of distant metastasis in papillary thyroid microcarcinomas. Thyroid 2016;26(1):161–8. DOI: 10.1089/thy.2015.0375</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Kim S.K., Park I., Woo J.W. et al. Total thyroidectomy versus lobectomy in conventional papillary thyroid microcarcinoma: analysis of 8676 patients at a single institution. Surgery 2017;161(2):485–92. DOI: 10.1016/j.surg.2016.07.037</mixed-citation><mixed-citation xml:lang="ru">Kim S.K., Park I., Woo J.W. et al. Total thyroidectomy versus lobectomy in conventional papillary thyroid microcarcinoma: analysis of 8676 patients at a single institution. Surgery 2017;161(2):485–92. DOI: 10.1016/j.surg.2016.07.037</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Siddiqui S., White M.G., Antic T. et al. Clinical and pathologic predictors of lymph node metastasis and recurrence in papillary thyroid microcarcinoma. Thyroid 2016;26(6):807–15. DOI: 10.1089/thy.2015.0429</mixed-citation><mixed-citation xml:lang="ru">Siddiqui S., White M.G., Antic T. et al. Clinical and pathologic predictors of lymph node metastasis and recurrence in papillary thyroid microcarcinoma. Thyroid 2016;26(6):807–15. DOI: 10.1089/thy.2015.0429</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Yu X.M., Wan Y., Sippel R.S., Chen H. Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18 445 cases. Ann Surg 2011;254(4):653–60. DOI: 10.1097/SLA.0b013e318230036d</mixed-citation><mixed-citation xml:lang="ru">Yu X.M., Wan Y., Sippel R.S., Chen H. Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18 445 cases. Ann Surg 2011;254(4):653–60. DOI: 10.1097/SLA.0b013e318230036d</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Mercante G., Frasoldati A., Pedroni C. et al. Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: results of a study in 445 patients. Thyroid 2009;19(7):707–16. DOI: 10.1089/thy.2008.0270</mixed-citation><mixed-citation xml:lang="ru">Mercante G., Frasoldati A., Pedroni C. et al. Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: results of a study in 445 patients. Thyroid 2009;19(7):707–16. DOI: 10.1089/thy.2008.0270</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Pazaitou-Panayiotou K., Capezzone M., Pacini F. Clinical features and therapeutic implication of papillary thyroid microcarcinoma. Thyroid 2007;17(11):1085–92. DOI: 10.1089/thy.2007.0005</mixed-citation><mixed-citation xml:lang="ru">Pazaitou-Panayiotou K., Capezzone M., Pacini F. Clinical features and therapeutic implication of papillary thyroid microcarcinoma. Thyroid 2007;17(11):1085–92. DOI: 10.1089/thy.2007.0005</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Pisanu A., Saba A., Podda M. et al. Nodal metastasis and recurrence in papillary thyroid microcarcinoma. Endocrine 2015;48(2):575– 81. DOI: 10.1007/s12020-014-0350-7</mixed-citation><mixed-citation xml:lang="ru">Pisanu A., Saba A., Podda M. et al. Nodal metastasis and recurrence in papillary thyroid microcarcinoma. Endocrine 2015;48(2):575– 81. DOI: 10.1007/s12020-014-0350-7</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Pyo J.S., Sohn J.H., Kang G. Detection of tumor multifocality is important for prediction of tumor recurrence in papillary thyroid microcarcinoma: a retrospective study and meta-analysis. J Pathol Transl Med 2016;50(4):278–86. DOI: 10.4132/jptm.2016.03.29</mixed-citation><mixed-citation xml:lang="ru">Pyo J.S., Sohn J.H., Kang G. Detection of tumor multifocality is important for prediction of tumor recurrence in papillary thyroid microcarcinoma: a retrospective study and meta-analysis. J Pathol Transl Med 2016;50(4):278–86. DOI: 10.4132/jptm.2016.03.29</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13. Ross D.S., Litofsky D., Ain K.B. et al. Recurrence after treatment of micropapillary thyroid cancer. Thyroid 2009;19(10):1043–8. DOI: 10.1089/thy.2008.0407</mixed-citation><mixed-citation xml:lang="ru">Ross D.S., Litofsky D., Ain K.B. et al. Recurrence after treatment of micropapillary thyroid cancer. Thyroid 2009;19(10):1043–8. DOI: 10.1089/thy.2008.0407</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14. Chow S.M., Law S.C., Chan J.K. et al. Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. Cancer 2003;98(1):31–40. DOI: 10.1002/cncr.11442</mixed-citation><mixed-citation xml:lang="ru">Chow S.M., Law S.C., Chan J.K. et al. Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. Cancer 2003;98(1):31–40. DOI: 10.1002/cncr.11442</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15. Ahn H.S., Kim H.J., Welch H.G. Korea’s thyroid-cancer “epidemic”: screening and overdiagnosis. New Engl J Med 2014;371(19):1765–7. DOI: 10.1056/NEJMp1409841</mixed-citation><mixed-citation xml:lang="ru">Ahn H.S., Kim H.J., Welch H.G. Korea’s thyroid-cancer “epidemic”: screening and overdiagnosis. New Engl J Med 2014;371(19):1765–7. DOI: 10.1056/NEJMp1409841</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16. Ahn H.S., Welch H.G. South Korea’s thyroid-cancer “epidemic”: turning the tide. New Engl J Med 2015;373(24):2389–90. DOI: 10.1056/NEJMc1507622</mixed-citation><mixed-citation xml:lang="ru">Ahn H.S., Welch H.G. South Korea’s thyroid-cancer “epidemic”: turning the tide. New Engl J Med 2015;373(24):2389–90. DOI: 10.1056/NEJMc1507622</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17. Ito Y., Miyauchi A., Kihara M. et al. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid 2014;24(1):27–34. DOI: 10.1089/thy.2013.0367</mixed-citation><mixed-citation xml:lang="ru">Ito Y., Miyauchi A., Kihara M. et al. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid 2014;24(1):27–34. DOI: 10.1089/thy.2013.0367</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">18. Lang B.H., Wong C.K. A cost-effectiveness comparison between early surgery and non-surgical approach for incidental papillary thyroid microcarcinoma. Eur J Endocrinol 2015;173(3):367–75. DOI: 10.1530/EJE-15-0454</mixed-citation><mixed-citation xml:lang="ru">Lang B.H., Wong C.K. A cost-effectiveness comparison between early surgery and non-surgical approach for incidental papillary thyroid microcarcinoma. Eur J Endocrinol 2015;173(3):367–75. DOI: 10.1530/EJE-15-0454</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">19. Kwak J.Y. Indications for fine needle aspiration in thyroid nodules. Endocrinol Metab 2013;28(2):81–5. DOI: 10.3803/EnM.2013.28.2.81</mixed-citation><mixed-citation xml:lang="ru">Kwak J.Y. Indications for fine needle aspiration in thyroid nodules. Endocrinol Metab 2013;28(2):81–5. DOI: 10.3803/EnM.2013.28.2.81</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">20. Haugen B.R., Alexander E.K., Bible K.C. et al. American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26(1):1– 133. DOI: 10.1089/thy.2015.0020</mixed-citation><mixed-citation xml:lang="ru">Haugen B.R., Alexander E.K., Bible K.C. et al. American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26(1):1– 133. DOI: 10.1089/thy.2015.0020</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">21. Lang B.H., Chan D.T., Chow F.C. et al. The association of discolored parathyroid glands and hypoparathyroidism following total thyroidectomy. World J Surg 2016;40(7):1611–7. DOI: 10.1007/s00268-016-3462-9</mixed-citation><mixed-citation xml:lang="ru">Lang B.H., Chan D.T., Chow F.C. et al. The association of discolored parathyroid glands and hypoparathyroidism following total thyroidectomy. World J Surg 2016;40(7):1611–7. DOI: 10.1007/s00268-016-3462-9</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">22. Bollerslev J., Rejnmark L., Marcocci C. et al. European Society of Endocrinology. European Society of Endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol 2015;173(2):G1–20. DOI: 10.1530/EJE-15-0628</mixed-citation><mixed-citation xml:lang="ru">Bollerslev J., Rejnmark L., Marcocci C. et al. European Society of Endocrinology. European Society of Endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol 2015;173(2):G1–20. DOI: 10.1530/EJE-15-0628</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">23. Bilimoria K.Y., Bentrem D.J., Ko C.Y. et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 2007;246(3):375–81, discussion 381–474. DOI: 10.1097/SLA.0b013e31814697d9</mixed-citation><mixed-citation xml:lang="ru">Bilimoria K.Y., Bentrem D.J., Ko C.Y. et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 2007;246(3):375–81, discussion 381–474. DOI: 10.1097/SLA.0b013e31814697d9</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">24. Mazzaferri E.L., Kloos R.T. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86(4):1447–63. DOI: 10.1210/jcem.86.4.7407</mixed-citation><mixed-citation xml:lang="ru">Mazzaferri E.L., Kloos R.T. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86(4):1447–63. DOI: 10.1210/jcem.86.4.7407</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">25. American Thyroid Association Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Cooper D.S., Doherty G.M., Haugen B.R. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19(11):1167–214. DOI: 10.1089/thy.2009.0110</mixed-citation><mixed-citation xml:lang="ru">American Thyroid Association Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Cooper D.S., Doherty G.M., Haugen B.R. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19(11):1167–214. DOI: 10.1089/thy.2009.0110</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">26. Nixon I.J., Ganly I., Patel S.G. et al. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. Surgery 2012;151(4):571–9. DOI: 10.1016/j.surg.2011.08.016</mixed-citation><mixed-citation xml:lang="ru">Nixon I.J., Ganly I., Patel S.G. et al. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. Surgery 2012;151(4):571–9. DOI: 10.1016/j.surg.2011.08.016</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">27. Barney B.M., Hitchcock Y.J., Sharma P. et al. Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. Head Neck 2011;33(5):645–9. DOI: 10.1002/hed.21504</mixed-citation><mixed-citation xml:lang="ru">Barney B.M., Hitchcock Y.J., Sharma P. et al. Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. Head Neck 2011;33(5):645–9. DOI: 10.1002/hed.21504</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">28. Haigh P.I., Urbach D.R., Rotstein L.E. Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer. Ann Surg Oncol 2005;12(1):81–9. DOI: 10.1007/s10434-004-1165-1</mixed-citation><mixed-citation xml:lang="ru">Haigh P.I., Urbach D.R., Rotstein L.E. Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer. Ann Surg Oncol 2005;12(1):81–9. DOI: 10.1007/s10434-004-1165-1</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">29. Kandil E., Krishnan B., Noureldine S.I. et al. Hemithyroidectomy: a meta-analysis of postoperative need for hormone replacement and complications. ORL J Otorhinolaryngol Its Relat Spec 2013;75(1):6–17. DOI: 10.1159/000345498</mixed-citation><mixed-citation xml:lang="ru">Kandil E., Krishnan B., Noureldine S.I. et al. Hemithyroidectomy: a meta-analysis of postoperative need for hormone replacement and complications. ORL J Otorhinolaryngol Its Relat Spec 2013;75(1):6–17. DOI: 10.1159/000345498</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">30. Hauch A., Al-Qurayshi Z., Randolph G., Kandil E. Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons. Ann Surg Oncol 2014;21(12):3844–52. DOI: 10.1245/s10434-014-3846-8</mixed-citation><mixed-citation xml:lang="ru">Hauch A., Al-Qurayshi Z., Randolph G., Kandil E. Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons. Ann Surg Oncol 2014;21(12):3844–52. DOI: 10.1245/s10434-014-3846-8</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">31. Han J.M., Kim W.G., Kim T.Y. et al. Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension. Thyroid 2014;24(5):820–5. DOI: 10.1089/thy.2013.0362</mixed-citation><mixed-citation xml:lang="ru">Han J.M., Kim W.G., Kim T.Y. et al. Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension. Thyroid 2014;24(5):820–5. DOI: 10.1089/thy.2013.0362</mixed-citation></citation-alternatives></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">32. Jeon M.J., Kim W.G., Choi Y.M. et al. Recent changes in the clinical outcome of papillary thyroid carcinoma with cervical lymph node metastasis. J Clin Endocrinol Metab 2015;100(9):3470–7. DOI: 10.1210/JC.2015-2084</mixed-citation><mixed-citation xml:lang="ru">Jeon M.J., Kim W.G., Choi Y.M. et al. Recent changes in the clinical outcome of papillary thyroid carcinoma with cervical lymph node metastasis. J Clin Endocrinol Metab 2015;100(9):3470–7. DOI: 10.1210/JC.2015-2084</mixed-citation></citation-alternatives></ref></ref-list></back></article>
